Not recruiting
Type 2 diabetes mellitus+3
Not recruitingEvaluating Once Daily Orforglipron (LY3502970) Compared to Insulin Glargine in Adults with Type 2 Diabetes and Obesity or Overweight who Have Increased Cardiovascular Risk
Registered drugNo placebo
Evaluating Once Daily Orforglipron (LY3502970) Compared to Insulin Glargine in Adults with Type 2 Diabetes and Obesity or Overweight who Have Increased Cardiovascular Risk
Registered drugNo placebo
- Disease:Type 2 diabetes mellitusObesity+2
- Substances:CanagliflozinDapagliflozin+5
Countries:
Austria
Austria- Participants:18–64 years · 65+ years
- Substances:Canagliflozin



